General surgery

General surgeons are often called to manage complex, high-acuity situations; bowel resections, abdominal wall defects, trauma coverage, or soft-tissue compromise.

These cases demand materials that:

Perform reliably in unpredictable environments
Support the body’s innate healing response
Handle efficiently in urgent OR workflows

General surgeons are often called to manage complex, high-acuity situations; bowel resections, abdominal wall defects, trauma coverage, or soft-tissue compromise.

These cases demand materials that:

Perform reliably in unpredictable environments
Support the body’s innate healing response
Handle efficiently in urgent OR workflows

Case studies

OASIS® Burn Matrix and OASIS® MICRO Micronized Wound Matrix in Left breast surgical wound

Pre-debridement: Significant necrotic tissue in ulcer base. Post-RT skin changes and peau d'orange.

Post-debridement: OASIS® MICRO Micronized Wound Matrix

2 weeks after the initial application of OASIS® MICRO Micronized Wound Matrix

6 days after 2nd application of OASIS MICRO Micronized Wound Matrix

Improved granulation and contracting after 3 applications of OASIS®

19 weeks

An 80-year-old non-smoking female presented with a non-healing radiation wound (18 sq cm, 54 cu cm) on her left breast, 7 months post-lumpectomy and 5 months post-radiation.

The patient was taken to the OR for debridement of the wound, which extended to the fascia and involved an inflammatory capsule. 500mg of OASIS MICRO Micronized Wound Matrix was applied. Post-operatively, a heavy growth of Enterobacter cloacae was found and treated. Four weeks later, the patient underwent a second OR debridement for a wound measuring 10 sq cm (20 cu cm), receiving a second 500mg OASIS MICRO application followed by NPWT.

The wound care plan then transitioned to in-clinic applications of OASIS Burn Matrix. After 11 total treatments, the wound was fully resolved.

Failed Sacral Myocutaneous Flap with Osteomyelitis

First Clinic visit: 8 Months after failed flap procedure

2 months of debridement and IODOSORB◊ Cadexomer Iodine

2 weeks before STRAVIX PL Tissue

STRAVIX PL Tissue Intra-op

Bolster of Xeroform™ and 4x4 gauze sutured in place with nylon

13 months post op

A 68-year-old male presented with a 6.6 x 5.0 x 0.5 cm Stage IV sacral pressure ulcer, present for two years. His history was significant for DM, protein malnutrition, Lynch Syndrome, osteomyelitis, and multiple prior failed flap surgeries, which left an exposed tendon.

The patient underwent excisional debridement, followed by the application of two 3x6cm STRAVIX PL Tissue grafts, which were secured with a bolster dressing.

Post-operatively, the patient managed poorly controlled blood sugars while simultaneously undergoing chemotherapy for 9 months and receiving Pembrolizumab for 12 months. Despite these systemic challenges, the sacral wound where the STRAVIX PL Tissue was placed continued to close, and the exposed bone was successfully covered.